Summaries and analysis of industry press releases
What’s Next for Corcept Therapeutics After FDA’s CRL for Relacorilant as a Treatment for Patients with Hypercortisolism Date: December 31,
In today’s fast pharma scene, brands act. Customer talk must hit, feel real. Channels mix—meet, talk, email, web. Pharma steers
Artificial intelligence (AI) shifts U.S. healthcare. AI touches care, tests, and drug find. AI screens images. AI spots new drugs.
In a significant shift aimed at enhancing its competitive edge in the biopharma industry, Novartis has announced a strategic workforce
The recent appointment of Richard Pazdur as the head of the FDA’s drug center has stirred up notable controversy and
The landscape of Alzheimer’s treatment took a notable downturn recently when Johnson & Johnson announced that its anti-tau monoclonal antibody
Navigating the complex landscape of pharmaceutical development requires a deep understanding of regulatory trends, market dynamics, and technological advances. In
In the intricate world of pharmaceutical regulation, the intersection of politics and science can greatly influence decision-making processes. Dr. Palak
November 21, 2025 HEADLINE FINDINGS: Alkermes escalates bidding war for Avadel Pharmaceuticals to $2.37 billion, intensifying competition for specialty CNS assets
In a significant turn of events, Ensoma, a Boston-based biotechnology startup dedicated to pioneering one-time genetic medicines, has announced drastic
Redemplo (plozasiran) cleared for familial chylomicronemia syndrome at $60,000 annual price—ten times lower than competitor Arrowhead Pharmaceuticals achieved a transformational
Biotech prepares FDA submission despite failing key pain crisis endpoint; shares plummet 47% on data release Agios Pharmaceuticals announced mixed
Agios Pharmaceuticals recently faced a substantial decline in its stock value following the announcement of mixed results from a Phase
BIOPHARMA EXECUTIVE INTELLIGENCE BRIEFING November 19, 2025 Headline Findings: Merck has announced a definitive agreement to acquire Cidara Therapeutics for
On November 18, 2025, Arrowhead Pharmaceuticals made a historic move by receiving the FDA approval for Redemplo, a groundbreaking treatment
In a bold move aimed at revitalizing American pharmaceutical research, FDA Commissioner Marty Makary has put forth a proposal to
The recent announcement from the White House about a new trade deal, aimed at capping tariffs on pharmaceutical imports from
In a bold move that signals its commitment to advancing cancer treatment, Johnson & Johnson (J&J) has announced a $3.05
On November 14, 2025, the U.S. Food and Drug Administration (FDA) made significant updates to the label of Sarepta Therapeutics’
In a significant shift in the biopharmaceutical landscape, Bristol Myers Squibb and Johnson & Johnson have announced the early termination